This quick guide helps clinicians address viral hepatitis when working with people living with substance use disorders. It covers hepatitis prevention, screening, treatment, and service coordination, and guides administrators on how to add or improve hepatitis services.

This advisory reviews diabetes and how it relates to mental illness, stress, and substance use disorders. It highlights ways to integrate diabetes care into behavioral health treatment, such as screening and intake, staff education, integrated care, and counseling support.

Gives patients information on buprenorphine and medication-assisted treatment for opioid addiction. Describes addiction and withdrawal, how buprenorphine works, its proper use, its side effects, and how it fits with counseling in the recovery process.

This guide offers strategies for communities on collaborating with faith-based organizations to address the service needs of people living with mental illness, substance use disorders, or both. It highlights examples, and presents challenges and benefits.

This report presents the key principles and core expectations of the State Epidemiological Outcomes Workgroups. The workgroups are designed to use data to inform and enhance state and community decisions regarding substance use and mental illness prevention programs.

This resource provides substance use treatment program administrators with information to implement tobacco-free policies and practices in treatment settings. It discusses challenges and strategies for developing clinical guidelines for treating tobacco dependence.

This advisory offers addiction counselors an introduction to tobacco use cessation during substance use treatment. It discusses screening and effective treatment approaches to quitting, and practical and supportive counseling.

This guide provides clinicians with questions to begin discussions with adult patients about mental illness, substance use disorders, or both. It includes resources for patients who need an evaluation after a positive screening.

This advisory defines protracted withdrawal and identifies specific withdrawal symptoms associated with alcohol, opioids, methamphetamine, cocaine, marijuana, and benzodiazepines. The advisory also explains how protracted withdrawal differs from acute withdrawal, and gives tips to help clients manage it in recovery.

This manual guides counselors in the use of medications to help clients achieve abstinence from alcohol. It describes how the medications work and whom may benefit. It also presents the side effects of three FDA-approved medications: acamprosate, disulfiram, and naltrexone.